| Alive Hospice Inc 1718 Patterson Road, Nashville, TN, 37203 | |
| (615) 327-1085 |
News Archive
As we grow older, our muscular function declines. A new study by researchers at Karolinska Institutet in Sweden shows how an unexpectedly high number of mutations in the stem cells of muscles impair cell regeneration.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal 2011, ended June 30, 2010.
A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
› Verified 6 days ago
| Name | Alive Hospice Inc |
|---|---|
| Location | 1718 Patterson Road, Nashville, Tennessee |
| Hospice ID | 441501 |
| Category | Freestanding Hospice |
| Ownership Type | Voluntary Non-profit - Private |
| Profit Type | NON-PROFIT |
| Accreditation Provider | The Joint Commission (TJC) |
| SSA county code | 180 |
News Archive
As we grow older, our muscular function declines. A new study by researchers at Karolinska Institutet in Sweden shows how an unexpectedly high number of mutations in the stem cells of muscles impair cell regeneration.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal 2011, ended June 30, 2010.
A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
› Verified 6 days ago
| NPI Number | 1184682858 |
| Organization Name | Alive Hospice, Inc |
| Address | 1718 Patterson St Nashville, Tennessee, 37203 |
| Phone Number | (615)327-1085 |
News Archive
As we grow older, our muscular function declines. A new study by researchers at Karolinska Institutet in Sweden shows how an unexpectedly high number of mutations in the stem cells of muscles impair cell regeneration.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal 2011, ended June 30, 2010.
A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
› Verified 6 days ago
| NPI Number | 1114241437 |
| Organization Name | Alive Hospice, Inc. |
| Address | 1718 Patterson St Nashville, Tennessee, 37203 |
| Phone Number | (615)327-1085 |
News Archive
As we grow older, our muscular function declines. A new study by researchers at Karolinska Institutet in Sweden shows how an unexpectedly high number of mutations in the stem cells of muscles impair cell regeneration.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal 2011, ended June 30, 2010.
A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
› Verified 6 days ago
| NPI Number | 1205022480 |
| Organization Name | Alive Hospice At St. Thomas Hospital |
| Address | 1718 Patterson St Nashville, Tennessee, 37203 |
| Phone Number | (615)327-1085 |
News Archive
As we grow older, our muscular function declines. A new study by researchers at Karolinska Institutet in Sweden shows how an unexpectedly high number of mutations in the stem cells of muscles impair cell regeneration.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal 2011, ended June 30, 2010.
A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
› Verified 6 days ago
| NPI Number | 1740772201 |
| Organization Name | |
| Address | 1718 Patterson St Nashville, Tennessee, 37203 |
| Phone Number | (615)306-9380 |
News Archive
As we grow older, our muscular function declines. A new study by researchers at Karolinska Institutet in Sweden shows how an unexpectedly high number of mutations in the stem cells of muscles impair cell regeneration.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal 2011, ended June 30, 2010.
A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
› Verified 6 days ago
| NPI Number | 1851587026 |
| Organization Name | Alive Hospice At Skyline Madison Campus |
| Address | 1718 Patterson St Nashville, Tennessee, 37203 |
| Phone Number | (615)327-1082 |
News Archive
As we grow older, our muscular function declines. A new study by researchers at Karolinska Institutet in Sweden shows how an unexpectedly high number of mutations in the stem cells of muscles impair cell regeneration.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal 2011, ended June 30, 2010.
A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
› Verified 6 days ago
| NPI Number | 1881643260 |
| Organization Name | Alive Hospice, Inc |
| Address | 1718 Patterson St Nashville, Tennessee, 37203 |
| Phone Number | (615)327-1085 |
News Archive
As we grow older, our muscular function declines. A new study by researchers at Karolinska Institutet in Sweden shows how an unexpectedly high number of mutations in the stem cells of muscles impair cell regeneration.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal 2011, ended June 30, 2010.
A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
› Verified 6 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 97.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 86.5 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 96.3 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 81.9 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 99.5 | 97.3 |
| Patients who got timely treatment for shortness of breath | 93.9 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 95.7 | 93.3 |
News Archive
As we grow older, our muscular function declines. A new study by researchers at Karolinska Institutet in Sweden shows how an unexpectedly high number of mutations in the stem cells of muscles impair cell regeneration.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal 2011, ended June 30, 2010.
A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
› Verified 6 days ago
| Home Health Aides | 43 |
| Counselors | 6 |
| Licensed Practical or Vocational Nurses | 10 |
| Medical Social Workers | 17 |
| Physicians | 6 |
| Registered Nurses | 99 |
| Other Personnel | 86 |
| Total Employees | 267 |
|---|
News Archive
As we grow older, our muscular function declines. A new study by researchers at Karolinska Institutet in Sweden shows how an unexpectedly high number of mutations in the stem cells of muscles impair cell regeneration.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal 2011, ended June 30, 2010.
A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
› Verified 6 days ago
| Others | 321 |
| Total Volunteers | 321 |
|---|
News Archive
As we grow older, our muscular function declines. A new study by researchers at Karolinska Institutet in Sweden shows how an unexpectedly high number of mutations in the stem cells of muscles impair cell regeneration.
Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal 2011, ended June 30, 2010.
A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
› Verified 6 days ago
| Alive Hospice Inc Location: 1718 Patterson Road, Nashville, Tennessee, 37203 Phone: (615) 327-1085 |
| Aseracare Hospice - Nashville Location: 441 Donelson Pike, Suite 400, Nashville, Tennessee, 37214 Phone: (615) 327-1085 |
| Avalon Hospice Location: 2525 Perimeter Place Drive, Suite 105, Nashville, Tennessee, 37214 Phone: (615) 327-1085 |
| Gentiva Hospice Location: 1400 Donelson Pike Suite B5, Nashville, Tennessee, 37217 Phone: (615) 327-1085 |